- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | CAMBIUM BIO LIMITED: Response to ASX Aware Query | 1 | ASX | ||
| Di | CAMBIUM BIO LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 11.04. | CAMBIUM BIO LIMITED: Change in substantial holding | - | ASX | ||
| 11.04. | CAMBIUM BIO LIMITED: Initial Director's Interest Notice - Tseng | - | ASX | ||
| 11.04. | CAMBIUM BIO LIMITED: Director Appointment Dr. Tseng | - | ASX | ||
| 10.04. | CAMBIUM BIO LIMITED: Placement Shares Cleansing Notice | - | ASX | ||
| 10.04. | CAMBIUM BIO LIMITED: Application for quotation of securities - CMB | - | ASX | ||
| 08.04. | REGENEUS LTD: Proposed issue of securities - RGS | - | ASX | ||
| 08.04. | REGENEUS LTD: Ceasing to be a substantial holder - Kirman 2 | - | ASX | ||
| 08.04. | REGENEUS LTD: Ceasing to be a substantial holder - Lee | - | ASX | ||
| 08.04. | REGENEUS LTD: Ceasing to be a substantial holder - Vesey | - | ASX | ||
| 08.04. | REGENEUS LTD: Change of Company Name and ASX Code | 1 | ASX | ||
| 05.04. | Australia's Cambium Bio eyes best day ever on completion of merger | 2 | Reuters | ||
| 05.04. | Regeneus and Cambium merge to refine dry eye treatment development | 1 | smallcaps.com.au | ||
| 05.04. | REGENEUS LTD: Cambium Bio Raises A$3.48 Million in Strategic Placement | - | ASX | ||
| 05.04. | REGENEUS LTD: Final Director's Interest Notice - Leo Lee | 1 | ASX | ||
| 05.04. | REGENEUS LTD: Director Resignation - Leo Lee | 1 | ASX | ||
| 05.04. | REGENEUS LTD: Notice of initial substantial holder | 1 | ASX | ||
| 05.04. | REGENEUS LTD: Initial Director's Interest Notice - Waller | - | ASX | ||
| 05.04. | REGENEUS LTD: Initial Director's Interest Notice - Walts | - | ASX |
Seite:
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERA THERAPEUTICS | 43,500 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| JANUX THERAPEUTICS | 62,43 | 0,00 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| SPRINGWORKS THERAPEUTICS | 43,320 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 52,20 | 0,00 % | Apogee Therapeutics, Inc.: Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases | Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 19,290 | 0,00 % | Edgewise Therapeutics: Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies | Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designations for sevasemten... ► Artikel lesen | |
| EVOTEC | 9,760 | -1,36 % | Evotec: Deutsche Bank reduziert Kursziel um 37 Prozent | Die Aktie von Evotec hat sich am Donnerstag nach dem massiven Einbruch zur Wochenmitte etwas stabilisiert. Zum Wochenschluss ging es zunächst nach unten, nachdem die Analysten der Deutschen Bank ihr... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 25,580 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,790 | 0,00 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| QIAGEN | 39,995 | +1,04 % | Ihre wichtigsten Termine: Heute im Fokus: Zahlen von Porsche AG, Philips, Qiagen, Vivendi und Bawag Group | © Foto: Porsche AG NewsroomGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:55... ► Artikel lesen | |
| C4 THERAPEUTICS | 6,430 | 0,00 % | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | WATERTOWN, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| CG ONCOLOGY | 39,500 | 0,00 % | CG Oncology Inc.: CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024 | ||
| AMGEN | 294,05 | +13,25 % | Amgen Aktie: Revolutionäre Therapie gegen Schilddrüsenaugenerkrankung | Der Biotechnologie-Konzern Amgen hat kürzlich Pläne bekannt gegeben, eine Zulassung für sein neuestes Medikament zur Behandlung einer schweren Autoimmunerkrankung bei der Europäischen Arzneimittel-Agentur... ► Artikel lesen | |
| ALX ONCOLOGY | 16,620 | 0,00 % | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | ||
| CULLINAN THERAPEUTICS | 27,540 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 4,910 | 0,00 % | Ventyx Biosciences, Inc.: Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event | VTX3232 was well-tolerated in the Phase 1 trial with robust target coverage achieved in both plasma and CSF; Ventyx is planning to initiate Phase 2a trials in Parkinson's disease and obesity in H2... ► Artikel lesen |
CAMBIUM BIO LIMITED gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
